Winton Group LTD Zymeworks Inc. Transaction History

Winton Group LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$15.19 - $29.33 $273,070 - $527,265	-17,977 Closed	0 $0
Q3 2021 Oct 28, 2021	SELL	$27.35 - $37.28 $170,636 - $232,589	-6,239 Reduced 25.76%	17,977 $522,000
Q2 2021 Aug 10, 2021	BUY	$26.5 - $38.23 $60,446 - $87,202	2,281 Added 10.4%	24,216 $840,000
Q1 2021 Jul 21, 2021	BUY	$29.83 - $56.81 $223,993 - $426,586	7,509 Added 52.05%	21,935 $693,000
Q4 2020 Feb 12, 2021	BUY	$39.12 - $54.99 $564,345 - $793,285	14,426 New	14,426 $682,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $906M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.